Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.

Assiut University90 enrolled

Overview

Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.

Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international inc., USA

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

serum AdiponectinDIAGNOSTIC_TEST

serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with fatty liver aged from 18 to 60 yrs either diabetic or not . * Patient with normal echogenic kidney in ultrasound and eGFR more than 60 mL/min/1.73m2. * The Control group are completely healthy subjects without any systemic or liver and kidney affection Exclusion Criteria: * Patients less than 18 yrs \& more than 60 yrs . * All patients having any other causes of renal and hepatic disease rather than Diabetes and having any other systemic problem.

Outcomes

Primary Outcomes

Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.

measure level of serum Adiponectin in non-alcoholic fatty liver patients to detect early renal impairment.

Time frame: baseline

Central Contacts

Hend Abdelrheem, Resident

CONTACT

01011062442 hendabdelrheem@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.